Sanofi’s Sarclisa (isatuximab) Receives EC’s Approval for adults with Relapsed and Refractory Multiple Myeloma

 Sanofi’s Sarclisa (isatuximab) Receives EC’s Approval for adults with Relapsed and Refractory Multiple Myeloma

Sanofi’s Sarclisa (isatuximab) Receives EC’s Approval for adults with Relapsed and Refractory Multiple Myeloma

Shots:

  • EC’s approval is based on P-III ICARIA-MM study assessing Sarclisa + (pomalidomide and dexamethasone) pom-dex vs pom-dex as monothx. for patients with r/r MM, prior treated with at least two therapies including lenalidomide and a proteasome inhibitor with progression on the last therapy
  • Results: mPFS (11.53 vs 6.47mos.); OS (60.4% vs 35.3%); In an additional analysis, the therapy showed benefits in patients with high risk cytogenetics, those aged ≥75yrs. with renal insufficiency and who were refractory to lenalidomide. The EC’s MAA for Sarclisa is applicable EU’s 27 states in addition to the UK, Iceland, Liechtenstein and Norway
  • Sarclisa is mAb targeting CD38 receptor on MM cells, act by inducing apoptosis & immunomodulatory activity and has received FDA’s approval on Mar 02, 2019. The company continues to evaluate Sarclisa in P-III clinical studies in combination with current standard treatments across the MM treatment continuum

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: StraitTimes

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post